SureTrader Advertisement Advertisement Advertisement
Home > Boards > US Listed > Biotechs >

Idera Pharmaceuticals, Inc. (IDRA)

Add IDRA Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Seel, Black sunshine
Search This Board:
Last Post: 11/30/2015 10:13:30 PM - Followers: 153 - Board type: Free - Posts Today: 0

The Company has created DNA-based compounds that in preclinical studies act as antagonists of TLR7 and TLR9, such as IMO-3100, or as antagonists of TLRs 7, 8, and 9, such as IMO-8400. The Company is developing IMO-3100, an antagonist of TLR7 and TLR9, for the treatment of psoriasis. It has selected IMO-8400, an antagonist of TLRs 7, 8, and 9, for development in the treatment of autoimmune diseases, with lupus as the initial disease indication. IMO-2055, a TLR9 agonist, is its lead drug candidate for the treatment of cancer. Clinical trials of IMO-2055 completed by the Company or by Merck KGaA include four Phase I clinical trials, of which two were in healthy subjects and two were in refractory cancer patients, and one Phase II clinical trial. The Phase II clinical trial was a monotherapy trial of IMO-2055 in patients with metastatic or recurrent clear cell renal cancer.

In preclinical animal models, the Company TLR7, 8, and 9 agonists have shown adjuvant activity when combined with various types of antigens. It has designed and created a new class of molecules to inhibit gene expression. These gene silencing oligonucleotides, which it refer to as GSOs, are nucleic acid-based and represent a novel approach to selectively, silence gene expression. It is actively engaged in preclinical research with its GSOs that is designed to explore their potential as research reagents and therapeutic agents. In addition to the Company’s clinical programs in autoimmune and inflammatory diseases and in cancer, it has identified TLR drug candidates for applications in the treatment of infectious diseases, respiratory diseases and hematological malignancies, and TLR3 agonists for use as vaccine adjuvants.

IMO-2125, a synthetic DNA-based TLR9 agonist, is its lead candidate for the treatment of chronic hepatitis C virus (HCV), infection. The Company conducted two Phase I clinical trials of IMO-2125 in patients with chronic HCV infection, one in patients with HCV who had not responded to prior treatment and one in combination with ribavirin, an antiviral medication approved for use in combination with interferon-alpha in the treatment of HCV infection, in treatment-naive patients with genotype 1 chronic HCV infection. In addition to the use of TLR9 agonists in oncology applications, it selected IMO-4200 as a lead TLR7 and TLR8 agonist candidate for the treatment of hematological cancers. Its TLR9 agonists are designed to induce immune responses that could be useful in restoring immune system balance. IMO-2134 is its lead TLR9 agonist for asthma and allergies. In addition to use of TLR7, 8, and 9 agonists as vaccine adjuvants, it also has created TLR3 agonists for potential use as vaccine adjuvants.

The Company competes with Dynavax Technologies Corporation, GlaxoSmithKline plc., Pfizer, Inc., VentiRx Pharmaceuticals., Novartis, Dynavax Technologies Corporation, VaxInnate, Inc., Intercell AG, Cytos Biotechnology AG and Celldex Therapeutics, Inc.



  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
IDRA News: Idera Pharmaceuticals Announces Several Key Leadership Additions 11/30/2015 08:00:00 AM
IDRA News: Idera to Collaborate With GSK to Identify 3rd Generation Antisense Molecules for Treatment of Renal Disease 11/23/2015 08:00:00 AM
IDRA News: Idera Announces Appointment of Joanna Horobin as Chief Medical Officer 11/18/2015 08:30:00 AM
IDRA News: Idera Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of IMO-8400 in Patients with Dermatomyositis 11/09/2015 08:00:00 AM
IDRA News: Quarterly Report (10-q) 11/06/2015 08:20:10 AM
News News Alert: Idera Pharmaceuticals Announces Several Key Leadership Additions 11/30/2015 08:00:00 AM
#718  Sticky Note Hi Seel. Let me assure you that despite ajsmith 03/09/14 01:35:35 AM
#2165   Piper Jaffray 'outperform' on IDRA: Canoepaddler 11/30/15 10:13:30 PM
#2164   Paddler, I find it far more important that Citrati 11/30/15 02:56:48 PM
#2163   Article out today,..$IDRA Canoepaddler 11/30/15 02:03:36 PM
#2162   What is the potential pps is everything comes Android 2-73 11/30/15 01:35:23 PM
#2161   TA analysis from yahoo: Canoepaddler 11/30/15 01:32:08 PM
#2160   4$ :-D Good to see that today ! Cbdpotential 11/30/15 11:36:43 AM
#2159   ;-) $idra Looking green to me ! Cbdpotential 11/30/15 11:34:32 AM
#2158   IMO, those are some VERY strong resumes. Citrati 11/30/15 10:11:02 AM
#2157   $IDRA. Oh My God!!! Seel 11/30/15 09:41:15 AM
#2156   Hole in the ground hole in the ground Cbdpotential 11/30/15 09:18:08 AM
#2155   Just read the news with a 'well, well, Seel 11/30/15 09:16:57 AM
#2154   THANK YOU :-D - - - Idera Pharmaceuticals Announces Several Cbdpotential 11/30/15 09:11:08 AM
#2153   I think so, but please don't make any Cbdpotential 11/30/15 08:36:19 AM
#2152   Think it's worth getting in now 3.60 ? Gregwit 11/30/15 08:34:58 AM
#2151   LOL, nice, thanks. DD or TA Citrati 11/30/15 12:57:24 AM
#2150   Besides Idra on Saturday from 5.30 to 7.30 stocking4ms 11/30/15 12:48:37 AM
#2149   Go $idra news please!? :-D Cbdpotential 11/29/15 11:34:13 PM
#2148   Have a great week. Should see more action Citrati 11/29/15 11:16:18 PM
#2147   Agree fully Citrati! Of course, you knew that Seel 11/29/15 11:12:09 PM
#2146   I find it quite interesting that such a Citrati 11/29/15 09:48:18 PM
#2145   Maybe not 5$ by January but 5$ in Cbdpotential 11/27/15 01:26:27 PM
#2144   It's a very Adam Smith-like post. Great read. Thanks! Seel 11/27/15 12:20:59 PM
#2143   What are you thinking this pps will rise Gregwit 11/27/15 08:04:36 AM
#2142   Interesting post from ymb:;_ylt=Akj Canoepaddler 11/26/15 04:50:44 PM
#2141   Baker Brothers stake in IDRA: Canoepaddler 11/26/15 03:28:32 PM
#2140   I think I'll jump in 3.50 and wait Gregwit 11/26/15 08:59:47 AM
#2139   Could I get more 3.1's? Cbdpotential 11/25/15 10:34:16 PM
#2138   Let's break 3.6 and see how that holds. Cbdpotential 11/25/15 09:50:43 PM
#2137   I agree Much more under the surface here... Risk profile Cbdpotential 11/25/15 12:02:20 PM
#2136   Cowen analyst comments & reiteration of Outperform on $IDRA: Canoepaddler 11/24/15 06:45:56 PM
#2135   Actually, I think it has more to do Citrati 11/24/15 04:12:46 PM
#2134   Ditto - should close nicely above the 200 Canoepaddler 11/24/15 03:40:25 PM
#2133   Bullish IMO Cbdpotential 11/24/15 02:44:01 PM
#2132   did not know this...have to add a lot more JUST 10-11-12 11/24/15 12:35:06 PM
#2131   3.2 Cbdpotential 11/24/15 11:16:04 AM
#2130   3.5 has always been a key level Cbdpotential 11/24/15 11:10:22 AM
#2129   Love the higher lows here since early September ;-) Cbdpotential 11/24/15 11:09:44 AM
#2128   $idra! Cbdpotential 11/24/15 10:56:18 AM
#2127   Thanks, Seel, that is potential for lots more green. Citrati 11/24/15 10:11:09 AM
#2126   Wow! My local Boston news station yesterday said Seel 11/24/15 09:34:12 AM
#2125   GSK 6th largest pharma in the world in Canoepaddler 11/23/15 11:55:50 PM
#2124   Is this a problem? or another collaboration?: north40000 11/23/15 06:43:15 PM
#2123   God. This is so sweet. All my baby Seel 11/23/15 06:02:25 PM
#2122   Best part IMO is "selected molecules". Citrati 11/23/15 01:52:31 PM
#2121   Fantastic news,..a baby $ISIS IMO. Canoepaddler 11/23/15 01:29:12 PM
#2120   Go $idra ! Cbdpotential 11/23/15 11:21:27 AM
#2119   Yep yep yep Cbdpotential 11/23/15 09:06:23 AM
#2118   CAMBRIDGE, Mass. and EXTON, Pa., Nov. 23, 2015 buckiii2 11/23/15 08:44:27 AM
#2117   IDRA should be over $4 this week. The stocking4ms 11/23/15 08:38:12 AM
#2116   Nice, a little patience will produce green if Citrati 11/22/15 09:18:34 PM